Wanlong Ma

Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.

Bi-clonal disease in patients with chronic lymphocytic leukaemia as detected by analysing IGHV mutation status.

Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.

Higher detection rate of JAK2 mutation using plasma.

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.

B-cell clones as early markers for chronic lymphocytic leukemia.

K-ras mutations and cetuximab in colorectal cancer.

Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.

BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.

Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia.

Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia.

JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.

Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.

MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.

Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease.

Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling.

BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease.

Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.

Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.

Synonymous Polymorphisms in HOXB13 as a Protective Factor for Prostate Cancer.

Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System.

Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome.

Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).

Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.